| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PD1 |
| Uniprot No | Q15116 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 25-167aa |
| 氨基酸序列 | LDSPDRPWNPPTFSPALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSN QTDKLAAFPEDRSQPGQDCRFRVTQLPNGRDFHMSVVRARRNDSGTYLCG AISLAPKAQIKESLRAELRVTERRAEVPTAHPSPSPRPAGQFQ |
| 预测分子量 | 17 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与PD-1重组蛋白相关的代表性文献摘要(基于公开研究整理，具体作者及年份为示例性描述)：
---
1. **文献名称**：*Structural basis of PD-1/PD-L1 interaction and therapeutic targeting*
**作者**：Zak KM et al.
**摘要**：该研究通过重组表达人源PD-1胞外域蛋白，解析了其与PD-L1复合物的晶体结构，揭示了二者结合的关键表位，为基于结构的抗PD-1抗体药物设计提供了理论依据。
---
2. **文献名称**：*Recombinant PD-1-Fc fusion protein enhances antitumor immunity by blocking PD-L1 in vivo*
**作者**：Chen L et al.
**摘要**：构建PD-1胞外域与IgG Fc的重组融合蛋白(PD-1-Fc)，证明其可通过竞争性结合PD-L1阻断免疫抑制信号，在黑色素瘤小鼠模型中显著抑制肿瘤生长并增强T细胞活性。
---
3. **文献名称**：*High-throughput screening of anti-PD-1 antibodies using recombinant PD-1 protein*
**作者**：Tan S et al.
**摘要**：利用重组PD-1蛋白建立体外高通量筛选平台，筛选出具有高亲和力的抗PD-1单克隆抗体，并验证其在恢复T细胞功能中的潜力，为临床抗体开发提供新方法。
---
注：以上文献信息为示例性概括，实际引用时请核对具体论文的标题、作者及内容细节。建议通过PubMed或Web of Science以“PD-1 recombinant protein”、“PD-1/PD-L1 structure”等关键词检索最新文献。
**Background of PD-1 Recombinant Protein**
Programmed cell death protein 1 (PD-1. CD279) is a critical immune checkpoint receptor expressed on activated T cells, B cells, and myeloid cells. It plays a pivotal role in maintaining immune homeostasis by suppressing excessive immune responses to prevent autoimmunity. PD-1 interacts with its ligands PD-L1 (B7-H1) and PD-L2 (B7-DC), which are often overexpressed in tumor cells or infected tissues, leading to T-cell exhaustion and immune evasion. Dysregulation of the PD-1/PD-L1 axis is closely associated with cancer progression, chronic infections, and autoimmune disorders.
Recombinant PD-1 protein is engineered through genetic modification, typically produced in mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper folding and post-translational modifications. It usually comprises the extracellular domain of PD-1. which retains ligand-binding capability. This protein serves as a vital tool for *in vitro* and *ex vivo* studies, enabling researchers to investigate PD-1/PD-L1 interaction mechanisms, screen for inhibitory antibodies or small molecules, and develop diagnostic assays.
In therapeutic development, recombinant PD-1 is used to validate checkpoint blockade strategies, mimicking natural receptor-ligand interactions during drug candidate evaluation. Notably, monoclonal antibodies targeting PD-1 (e.g., pembrolizumab, nivolumab) have revolutionized cancer immunotherapy, highlighting the translational significance of studying this protein. Beyond oncology, recombinant PD-1 aids in exploring autoimmune disease mechanisms and vaccine adjuvants by modulating T-cell activation thresholds. Its versatility underscores its importance in both basic immunology research and clinical applications.
×
